Galectin Therapeutics Inc., the leading developer of therapeutics targeting galectin proteins, has reported its financial results for the first quarter of 2025. The company recorded a net loss applicable to common stockholders of $9.6 million for the quarter ended March 31, 2025, which is an improvement from the net loss of $11.5 million for the same period in 2024. General and administrative expenses decreased to $1.4 million from $1.6 million in the previous year. Research and development expenses also saw a reduction, amounting to $6.5 million compared to $8.1 million for the same period in 2024. This decrease was primarily due to the timing of expenditures related to the NAVIGATE clinical trial. As of March 31, 2025, Galectin Therapeutics had $7.4 million in cash and cash equivalents, with an additional $11 million available under two lines of credit from its chairman of the board. The company expects these funds to support operations and research and development activities through August 2025. Significant progress was highlighted in the NAVIGATE trial, with statistically significant reductions in liver stiffness observed in the belapectin 2 mg/kg treatment arm at various intervals: a mean change from baseline of -3.48 kPa at Week 26, -4.60 kPa at Week 52, and further positive results at Week 78. These findings were presented at the European Association for the Study of the Liver Congress on May 10, 2025.